FDA
-
-
-
-
-
-
-
BioCardia reports trial shows cell therapy improves heart symptoms
-
-
-
-
-
-
-
BioCardia receives positive PMDA feedback for CardiAMP therapy in Japan
-
-
-
-
-
-
-
BioCardia Late Breaking Echocardiography Clinical Results from CardiAMP HF Trial Presented at Technology and Heart Failure Therapeutics (THT)
-
-
-
-
-
-
-
BioCardia Reports Third Quarter 2025 Business Highlights and Financial Results
-
-
-
-
-
-
-
BioCardia CEO Peter Altman to Present at the H. C. Wainwright 27th Annual Global Investment Conference in New York City September 8-10, 2025
-
-
-
-
-
-
-
Henry Ford Health Initiates Patient Enrollment for BioCardia’s CardiAMP HF II Pivotal Study for Ischemic Heart Failure of Reduced Ejection Fraction
-
-
-
-
-
-
-
Biocardia Phase 3 CardiAMP-HF Trial of Novel Cardiac Cell Therapy for Ischemic Heart Failure Shows Increased Survival, Decreased Cardiac Events, and Improved Quality of Life at Two Years
-
325,893 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

